Company Overview and News

Kabuni to reveal next steps with Print the Future

Kabuni Ltd's (ASX:KBU) shares are in pre-open following the ASX granting the company a trading halt.

Kabuni's shares halted pending transaction update

Kabuni Ltd (ASX:KBU) has been granted a trading halt by the ASX, pending an update on the transaction with Print the Future (PTF).

Kabuni looks in a new direction

Kabuni (ASX:KBU) has been granted a trading halt by the ASX, pending a potential change in control transaction.

Kabuni Ltd partners with to promote home décor marketplace

Kabuni Ltd (ASX:KBU) has entered into a partnership with to promote Kabuni’s online home décor and interior designs marketplace to’s users. is an online marketplace that helps vacation rental homeowners find a property manager to manage their property. Over the course of the 12-month partnership, Kabuni will promote its platform to’s users, which include over 600 property managers and 5,000 homeowners from 60 countries.

Kabuni Ltd upgrades interior designing app to drive revenue growth

Kabuni Ltd (ASX:KBU) has released version 2.0 of its mobile platform with significant upgrades which are expected to drive the company's revenue growth. The Kabuni platform allows interior designers collaborate directly with homeowners and earn income from the sale of custom-made home and interior designs. As of July, Kabuni had 1,212 designers registered and is adding an average 35 designers per week.

Appendix 3B


Kabuni Ltd gains traction with client and designer matching app

Kabuni Ltd (ASX:KBU) formerly Whole New Home is a North American based e-commence Software as a Service platform which connects home designers directly with home owners and tenants.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...